ICICI Prudential NIFTY Pharma Index Fund - Direct Plan - Growth
ICICI Prudential Asset Management Company Limited · Direct Plan · Growth
Fund overview
Nil
Returns & rankings
| Period | Fund Returns | Category Avg. | Rank | VS Category |
|---|---|---|---|---|
| … | ||||
Green = fund outperformed the category average for that period; red = underperformed. Periods under 1 year always show absolute (non-annualised) returns. Past performance does not guarantee future returns.
Return calculator
One-time investment
₹1,000
| Over the past | Total investment | Would've become | Returns |
|---|---|---|---|
| 1 Year | ₹1,000 | ₹1,191 | +191 |
| 3 Years | ₹1,000 | ₹1,689 | +689 |
| 5 Years | ₹1,000 | ₹2,395 | +1,395 |
Calculated using the fund's annualised return since inception (19.1% p.a.) as period-wise historical returns aren't available in the current feed. Actual returns fluctuate and are not guaranteed. Mutual fund investments are subject to market risks.
Holdings
20 securitiesTop 10 holdings make up 75.0% of the portfolio.
| Security | Sector | Market Cap | Weight |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals & Biotechnology | Large Cap | 19.50% |
| Divi'S Laboratories Ltd | Pharmaceuticals & Biotechnology | Large Cap | 11.97% |
| Laurus Labs Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 7.82% |
| Cipla Ltd | Pharmaceuticals & Biotechnology | Large Cap | 7.68% |
| Dr. Reddys Laboratories Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 7.62% |
| Torrent Pharmaceuticals Ltd | Pharmaceuticals & Biotechnology | Large Cap | 7.16% |
| Lupin Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 5.00% |
| Aurobindo Pharma Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 4.68% |
| Glenmark Pharmaceuticals Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 3.56% |
| Alkem Laboratories Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 3.16% |
Portfolio Allocation
Equity / Debt / Cash
Total Value
₹163 Cr
Market Cap Split
Total Value
100%
Equity sector allocation
Total Value
₹163 Cr
Exit load, stamp duty & tax
25-Nov-22
Nil
0.005% (from July 1st, 2020)
Taxation depends on the fund category and holding period. Consult the scheme document or a tax advisor for details.
Risk & Performance Ratios (1Y)
| Standard Deviation | 17.07% |
| Beta | 1.02 |
| Sharpe Ratio | 2.10 |
| Sortino Ratio | -0.64 |
| Treynor Ratio | 0.35 |
| Jensen's Alpha | -3.20 |
| Information Ratio | -0.80 |
| R-Squared | 99.82% |
| Max Drawdown | -5.61% |
| Upside Capture | 96.39% |
| Downside Capture | 110.16% |
Fund management
Scheme Details
Investment objective
The Objective Of The Scheme Is To Invest In Companies Whose Securities Are Included In Nifty Pharma Index And Subject To Tracking Errors, To Endeavor To Achieve The Returns Of The Above Index. This Would Be Done By Investing In All The Stocks Comprising The Nifty Pharma Index In The Same Weightage That They Represent In Nifty Pharma Index. However, There Is No Assurance Or Guarantee That The Investment Objective Of The Scheme Shall Be Achieved.
Fund house
ICICI Prudential Asset Management Company Limited
Frequently asked questions
What is the NAV of ICICI Prudential NIFTY Pharma Index Fund - Direct Plan - Growth?
The NAV of ICICI Prudential NIFTY Pharma Index Fund - Direct Plan - Growth is ₹19.79 as of 21 Oct 2026. NAV is updated at the end of every trading day.
How much expense ratio is charged by ICICI Prudential NIFTY Pharma Index Fund - Direct Plan - Growth?
The expense ratio charged by ICICI Prudential NIFTY Pharma Index Fund - Direct Plan - Growth is 0.51%.
What is the Min. SIP of ICICI Prudential NIFTY Pharma Index Fund - Direct Plan - Growth?
The minimum SIP investment in ICICI Prudential NIFTY Pharma Index Fund - Direct Plan - Growth is ₹1,000 per month.
What is the Min. Lumpsum of ICICI Prudential NIFTY Pharma Index Fund - Direct Plan - Growth?
The minimum lumpsum investment in ICICI Prudential NIFTY Pharma Index Fund - Direct Plan - Growth is ₹1,000.
What is the Exit Load of ICICI Prudential NIFTY Pharma Index Fund - Direct Plan - Growth?
ICICI Prudential NIFTY Pharma Index Fund - Direct Plan - Growth does not charge an exit load.
.svg){kind=small}